Genome recognition by MYC

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 2, 2014, Pages

  Sabò, Arianna ^a   Amati, Bruno ^a,b  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; GENOMIC DNA; HEAT SHOCK TRANSCRIPTION FACTOR 1; HISTONE ACETYLTRANSFERASE; MAX PROTEIN; MYC PROTEIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION; GENETIC ANALYSIS; GENOME ANALYSIS; HUMAN; MOLECULAR RECOGNITION; PHYSIOLOGY; PROTEIN INTERACTION; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

ENHANCER ELEMENTS, GENETIC; EPISTASIS, GENETIC; GENES, MYC; GENOME, HUMAN; HUMANS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84893233590     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014191     Document Type: Article

References (128)

1. Adhikary S, Eilers M. 2005. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645.
2. Allard S, Utley RT, Savard J, Clarke A, Grant P, Brandl CJ, Pillus L, Workman JL, Cote J. 1999. NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM-related cofactor Tra1p. EMBO J 18: 5108-5119.
3. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. 1992. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359: 423-426.
4. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. 1993a. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72: 233-245.
5. Amati B, Littlewood TD, Evan GI, Land H. 1993b. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 12: 5083-5087.
6. Arvey A, Agius P, Noble WS, Leslie C. 2012. Sequence and chromatin determinants of cell-type-specific transcription factor binding. Genome Res 22: 1723-1734.
7. Ayer DE, Kretzner L, Eisenman RN. 1993. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72: 211-222.
8. Blackwell TK, Weintraub H. 1990. Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science 250: 1104-1110.
9. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. 1990. Sequence-specific DNA binding by the c-Myc protein. Science 250: 1149-1151.
10. Blackwell TK, Huang J, Ma A, Kretzner L, Alt FW, Eisenman RN, Weintraub H. 1993. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol 13: 5216-5224.
11. Blackwood EM, Eisenman RN. 1991. Max: A helix-loophelix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217.
12. Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M, Luscher B. 2001. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev 15: 2042-2047.
13. Bouchard C, Marquardt J, Brás A, Medema RH, Eilers M. 2004. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J 23: 2830-2840.
14. Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, Gutiérrez A, Danovi D, Bernard D, Boon T, et al. 2005. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 24: 336-346.
15. Cave JW, Kremer W, Wemmer DE. 2000. Backbone dynamics of sequence specific recognition and binding by the yeast Pho4 bHLH domain probed by NMR. Protein Sci 9: 2354-2365.
16. Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV. 1999. c-MYC interactswith INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22: 102-105.
17. Cheng ASL, Jin VX, Fan M, Smith LT, Liyanarachchi S, Yan PS, Leu Y-W, Chan MWY, Plass C, Nephew KP, et al. 2006. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-a responsive promoters. Mol Cell 21: 393-404.
18. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, et al. 2009. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 69: 8491-8498.
19. Cohen SL, Ferré-D'Amaré AR, Burley SK, Chait BT. 1995. Probing the solution structure of the DNA-binding protein Max by a combination of proteolysis and mass spectrometry. Protein Sci 4: 1088-1099.
20. Conacci-Sorrell M, McFerrin L, Eisenman RN. 2014. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4: a014327.
21. Cowling VH, Cole MD. 2007. The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol 27: 2059-2073.
22. Deaton AM, Bird A. 2011. CpG islands and the regulation of transcription. Genes Dev 25: 1010-1022.
23. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R. 2007. Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451.
24. Doyon Y, Selleck W, Lane WS, Tan S, Cĉté J. 2004. Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol Cell Biol 24: 1884-1896.
25. Eberhardy SR. 2002. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J Biol Chem 277: 40156-40162.
26. Eberhardy SR, Farnham PJ. 2001. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J Biol Chem 276: 48562-48571.
27. Edelman LB, Fraser P. 2012. Transcription factories: Genetic programming in three dimensions. Curr Opin Genet Dev 22: 110-114.
28. Efstratiadis A, Szabolcs M, Klinakis A. 2007. Notch, Myc and breast cancer. Cell Cycle 6: 418-429.
29. Eilers M, Eisenman RN. 2008. Myc's broad reach. Genes Dev 22: 2755-2766.
30. ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 488: 57-74.
31. Felsher DW. 2010. MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 1: 597-604.
32. Felsher DW, Bishop JM. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207.
33. Ink4B. Mol Cell 9: 133-143.
34. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. 2003. Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
35. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. 2001. Binding of c-Myc to chromatin mediates mitogeninduced acetylation of histone H4 and gene activation. Genes Dev 15: 2069-2082.
36. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan H-M, Livingston DM, Amati B. 2003. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep 4: 575-580.
37. Gabay M, Li Y, Felsher DW. 2014. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014241.
38. Gallant P. 2013. Myc function in Drosophila. Cold Spring Harb Perspect Med 3: a014324.
39. Gallant P, Steiger D. 2009. Myc's secret lifewithout Max. Cell Cycle 8: 3848-3853.
40. (WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci 98: 4510-4515.
41. Giorgetti L, Siggers T, Tiana G, Caprara G, Notarbartolo S, Corona T, Pasparakis M, Milani P, Bulyk ML, Natoli G. 2010. Noncooperative interactions between transcription factors and clustered DNA binding sites enable graded transcriptional responses to environmental inputs. Mol Cell 37: 418-428.
42. Gomez-Roman N, Grandori C, Eisenman RN, White RJ. 2003. Direct activation of RNA polymerase III transcription by c-Myc. Nature 421: 290-294.
43. Graves JA, Wang Y, Sims-Lucas S, Cherok E, Rothermund K, Branca MF, Elster J, Beer-Stolz D, Van Houten B, Vockley J, et al. 2012. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS ONE 7: e37699.
44. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall Olio V, Zardo G, Nervi C, Bernard L, Amati B. 2006. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 8: 764-770.
45. Guertin MJ, Lis JT. 2012. Mechanisms by which transcription factors gain access to target sequence elements in chromatin. Curr Opin Genet Dev 23: 116-123.
46. Guertin MJ, Martins AL, Siepel A, Lis JT. 2012. Accurate prediction of inducible transcription factor binding intensities in vivo ed. M. Snyder. PLoS Genet 8: e1002610.
47. Hann S. 2014. Myc protein interactions. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014399.
48. Hateboer G, Timmers HT, Rustgi AK, Billaud M, van 't Veer LJ, Bernards R. 1993. TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. Proc Natl Acad Sci 90: 8489-8493.
49. Herkert B, Eilers M. 2010. Transcriptional repression: The dark side of myc. Genes Cancer 1: 580-586.
50. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T, Syvaoja J, Saluz H-P, Haenel F, Eilers M. 2002. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 10: 509-521.
51. Hurlin PJ, Queva C, Koskinen PJ, Steingrímsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN. 1995. Mad3 and Mad4: NovelMax-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 14: 5646-5659.
52. Hurlin PJ, Queva C, Eisenman RN. 1997. Mnt, a novel Maxinteracting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev 11: 44-58.
53. Iritani BM, Eisenman RN. 1999. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci 96: 13180-13185.
54. Izumi H, Molander C, Penn LZ, Ishisaki A, Kohno K, Funa K. 2001. Mechanism for the transcriptional repression by c-Myc on PDGF b-receptor. J Cell Sci 114: 1533-1544.
55. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102-104.
56. James L, Eisenman RN. 2002. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo. Proc Natl Acad Sci 99: 10429-10434.
57. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. 2007. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus Type 1 promoter. J Virol 81: 10914-10923.
58. Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P. 1999. Drosophila myc regulates cellular growth during development. Cell 98: 779-790.
59. Kaplan T, Li X-Y, Sabo PJ, Thomas S, Stamatoyannopoulos JA, Biggin MD, Eisen MB. 2011. Quantitative models of the mechanisms that control genome-wide patterns of transcription factor binding during early Drosophila development. PLoS Genet 7: e1001290.
60. Kerosuo L, Piltti K, Fox H, Angers-Loustau A, Häyry V, Eilers M, Sariola H, Wartiovaara K. 2008. Myc increases self-renewal in neural progenitor cells through Miz-1. J Cell Sci 121: 3941-3950.
61. Kim J, Chu J, Shen X, Wang J, Orkin SH. 2008. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132: 1049-1061.
62. Koch HB, Zhang R, Verdoodt B, Bailey A, Zhang C-D, Yates JR, Menssen A, Hermeking H. 2007. Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell Cycle 6: 205-217.
63. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128: 693-705.
64. Kretzner L, Blackwood EM, Eisenman RN. 1992. Myc and Max proteins possess distinct transcriptional activities. Nature 359: 426-429.
65. Küppers R, Dalla-Favera R. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20: 5580-5594.
66. Kurland JF, Tansey WP. 2008. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 68: 3624-3629.
67. Lebel R, McDuff F-O, Lavigne P, Grandbois M. 2007. Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-Box sequences on the hTERT promoter. Biochemistry 46: 10279-10286.
68. Lee B-K, Bhinge AA, Battenhouse A, McDaniell RM, Liu Z, Song L, Ni Y, Birney E, Lieb JD, Furey TS, et al. 2012. Celltype specific and combinatorial usage of diverse transcription factors revealed by genome-wide binding studies in multiple human cells. Genome Res 22: 9-24.
69. Levens D. 2013. Cellular MYCro economics: BalancingMYC function with MYC expression. Cold Spring Harb Perspect Med 3: a014233.
70. Li Z. 2003. A global transcriptional regulatory role forc-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci 100: 8164-8169.
71. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, Kim J-W, Yustein JT, Lee LA, Dang CV. 2005. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25: 6225-6234.
72. Lickwar CR, Mueller F, Hanlon SE, McNally JG, Lieb JD. 2012. Genome-wide protein-DNA binding dynamics suggest a molecular clutch for transcription factor function. Nature 484: 251-255.
73. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
74. Liu X, Vorontchikhina M, Wang Y-L, Faiola F, Martinez E. 2008. STAGA recruits Mediator to the MYC oncoprotein to stimulate transcription and cell proliferation. Mol Cell Biol 28: 108-121.
75. Luscher-Firzlaff J, Gawlista I, Vervoorts J, Kapelle K, Braunschweig T, Walsemann G, Rodgarkia-Schamberger C, Schuchlautz H, Dreschers S, Kremmer E, et al. 2008. The human trithorax protein hASH2 functions as an oncoprotein. Cancer Res 68: 749-758.
76. Mao DYL, Watson JD, Yan PS, Barsyte-Lovejoy D, Khosravi F, Wong WW-L, Farnham PJ, Huang THM, Penn LZ. 2003. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol 13: 882-886.
77. Marguerat S, Bähler J. 2012. Coordinating genome expression with cell size. Trends Genet 28: 560-565.
78. Martinato F, Cesaroni M, Amati B, Guccione E, Abraham E. 2008. Analysis of Myc-induced histone modifications on target chromatin. PLoS ONE 3: e3650.
79. Matsuoka Y, Fukamachi K, Uehara N, Tsuda H, Tsubura A. 2008. Induction of a novel histone deacetylase 1/c-Myc/ Mnt/Max complex formation is implicated in parityinduced refractoriness to mammary carcinogenesis. Cancer Sci 99: 309-315.
80. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. 1998. The novelATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94: 363-374.
81. Mukherjee B, Morgenbesser SD, DePinho RA. 1992. Myc family oncoproteins function through a common pathway to transform normal cells in culture: Cross-interference by Max and trans-acting dominant mutants. Genes Dev 6: 1480-1492.
82. Nagy Z, Tora L. 2007. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26: 5341-5357.
83. Nair SK, Burley SK. 2003. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112: 193-205.
84. Neph S, Vierstra J, Stergachis AB, Reynolds AP, Haugen E, Vernot B, Thurman RE, John S, Sandstrom R, Johnson AK, et al. 2012. An expansive human regulatory lexicon encoded in transcription factor footprints. Nature 488: 83-90.
85. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem Cells. Cell 151: 68-79.
86. Nikiforov MA. 2003. The Mad and Myc basic domains are functionally equivalent. J Biol Chem 278: 11094-11099.
87. Orian A. 2003. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev 17: 1101-1114.
88. Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J, Tempst P, Sif S. 2003. mSin3A/histone deacetylase 2-and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol 23: 7475-7487.
89. Park J, Wood MA, Cole MD. 2002. BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation. Mol Cell Biol 22: 1307-1316.
90. Patel JH. 2005. Targeting of Miz-1 is essential for Mycmediated apoptosis. J Biol Chem 281: 3283-3289.
91. Perna D, Fagà G, Verrecchia A, Gorski MM, Barozzi I, Narang V, Khng J, Lim KC, Sung W-K, Sanges R, et al. 2012. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene 31: 1695-1709.
92. Pique-Regi R, Degner JF, Pai AA, Gaffney DJ, Gilad Y, Pritchard JK. 2011. Accurate inference of transcription factor binding from DNA sequence and chromatin accessibility data. Genome Res 21: 447-455.
93. Rahl PB, Young RA. 2014. Myc and transcription elongation. Cold Spring Harb Perspect Med 4: a014340.
94. Rahl PB, Lin CY, Seila AC, Flynn RA, Mccuine S, Burge CB, Sharp PA, Young RA. 2010. c-Myc regulates transcriptional pause release. Cell 141: 432-445.
95. Ridinger-Saison M, Boeva V, Rimmele P, Kulakovskiy I, Gallais I, Levavasseur B, Paccard C, Legoix-Ne P, Morle F, Nicolas A, et al. 2012. Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia. Nucleic Acids Res 40: 8927-8941.
96. Roussel MF, Robinson GW. 2013. Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med 3: a014308.
97. Roy AL, Carruthers C, Gutjahr T, Roeder RG. 1993. Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature 365: 359-361.
98. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR. 2007. Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676-679.
99. Satou A. 2001. A novel transrepression pathway of c-Myc. Recruitment of a transcriptional corepressor complex to c-Myc by MM-1, a c-Myc-binding protein. J Biol Chem 276: 46562-46567.
100. Sauvé S, Naud J-F, Lavigne P. 2007. The mechanism of discrimination between cognate and non-specific DNA by dimeric b/HLH/LZ transcription factors. JMol Biol 365: 1163-1175.
101. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. 2012. Linking disease associations with regulatory information in the human genome. Genome Res 22: 1748-1759.
102. Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, Eick D, Kohlhuber F. 1999. Control of cell growth by c-Myc in the absence of cell division. Curr Biol 9: 1255-1258.
103. Schmitz R, Ceribelli M, Pittaluga S, Wrigth G, Staudt LM. 2014. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014282.
104. Secombe J, Li L, Carlos L, Eisenman RN. 2007. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev 21: 537-551.
105. Segal E, Widom J. 2009. From DNA sequence to transcriptional behaviour: A quantitative approach. Nat Rev Genet 10: 443-456.
106. Segal E, Raveh-Sadka T, Schroeder M, Unnerstall U, Gaul U. 2008. Predicting expression patterns from regulatory sequence in Drosophila segmentation. Nature 451: 535-540.
107. Seitz V, Butzhammer P, Hirsch B, Hecht J, Gütgemann I, Ehlers A, Lenze D, Oker E, Sommerfeld A, Wall Von Der E, et al. 2011. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS ONE 6: e26837.
108. INK4b. Nat Cell Biol 3: 400-408.
109. Sha M, Ferré-D'Amaré AR, Burley SK, Goss DJ. 1995. Anticooperative biphasic equilibrium binding of transcription factor upstream stimulatory factor to its cognate DNA monitored by protein fluorescence changes. J Biol Chem 270: 19325-19329.
110. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117.
111. Sharma VM, Draheim KM, Kelliher MA. 2007. The Notch1/c-Myc pathway in T cell leukemia. Cell Cycle 6: 927-930.
112. Shrivastava A, Saleque S, Kalpana GV, Artandi S, Goff SP, Calame K. 1993. Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc. Science 262: 1889-1892.
113. Solomon DL, Amati B, Land H. 1993. Distinct DNAbinding preferences for the c-Myc/Max and Max/Max dimers. Nucleic Acids Res 21: 5372-5376.
114. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
115. Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN, Swigart LB, Evan GI. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27: 504-513.
116. Soufi A, Donahue G, Zaret KS. 2012. Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell 151: 994-1004.
117. INK4b expression by Myc through association with Miz-1. Nat Cell Biol 3: 392-399.
118. Steiger D, Furrer M, Schwinkendorf D, Gallant P. 2008. Max independent functions of Myc in Drosophila melanogaster. Nat Genet 40: 1084-1091.
119. Uribesalgo I, Buschbeck M, Gutiérrez A, Teichmann S, Demajo S, Kuebler B, Nomdedéu JF, Martín-Caballero J, Roma G, Benitah SA, et al. 2011. E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol.
120. van Riggelen J, Muller J, Otto T, Beuger V, Yetil A, Choi PS, Kosan C, Möröy T, Felsher DW, Eilers M. 2010. The interaction between Myc and Miz1 is required to antagonize TGF-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 24: 1281-1294.
121. Vervoorts J, Luscher B. 1999. DNA binding of Myc/Max/ Mad network complexes to oligonucleotides containing two E box elements: c-Myc/Max heterodimers do not bind DNA cooperatively. Biol Chem 380: 1121-1126.
122. Vervoorts J, Lüscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, Austen M, Lüscher B. 2003. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep 4: 484-490.
123. Walhout AJ, Gubbels JM, Bernards R, van der Vliet PC, Timmers HT. 1997. c-Myc/Max heterodimers bind cooperatively to the E-box sequences located in the first intron of the rat ornithine decarboxylase (ODC) gene. Nucleic Acids Res 25: 1493-1501.
124. Wang J, Zhuang J, Iyer S, Lin X, Whitfield TW, Greven MC, Pierce BG, Dong X, Kundaje A, Cheng Y, et al. 2012. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res 22: 1798-1812.
125. Wiese K, Walz S, von Eyss B, Wolf E, Athineos D, Sansom O, Eilers M. 2013. The role of Miz1 in the Myc-dependent tumorigenesis. Cold Spring Harb Perspect Med 3: a014290.
126. Wilkins JA, Sansom OJ. 2008. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res 68: 4963-4966.
127. Zeller KI, Zhao X, Lee CWH, Chiu K-P, Yao F, Yustein JT, Ooi HS, Orlov YL, Shahab A, Yong HC, et al. 2006. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci 103: 17834-17839.
128. Zervos AS, Gyuris J, Brent R. 1993. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72: 223-232.